TIK-301

TIK-301 is a pharmaceutical compound that has been investigated for its potential use in the treatment of various neurological disorders. It is also known by its chemical name, Tianeptine.
Mechanism of Action[edit]
TIK-301 is believed to function primarily as a serotonin reuptake enhancer (SRE). Unlike typical antidepressants that inhibit the reuptake of serotonin, TIK-301 enhances the reuptake process, leading to a decrease in extracellular serotonin levels. This unique mechanism differentiates it from other selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
Clinical Uses[edit]
TIK-301 has been studied for its potential efficacy in treating major depressive disorder (MDD), anxiety disorders, and post-traumatic stress disorder (PTSD). Clinical trials have shown mixed results, and further research is needed to fully understand its therapeutic potential and safety profile.
Side Effects[edit]
The side effects of TIK-301 are similar to those of other antidepressants and may include nausea, dizziness, insomnia, and dry mouth. Long-term use and its effects are still under investigation.
Regulatory Status[edit]
As of now, TIK-301 has not been approved by major regulatory bodies such as the Food and Drug Administration (FDA) for clinical use. It remains an investigational drug, and its approval status may change pending the results of ongoing and future clinical trials.
Research and Development[edit]
TIK-301 is the subject of ongoing research to better understand its pharmacological properties and potential therapeutic applications. Studies are being conducted to explore its efficacy in comparison to other antidepressants and its potential use in combination therapies.
See Also[edit]
- Tianeptine
- Serotonin reuptake enhancer
- Major depressive disorder
- Anxiety disorders
- Post-traumatic stress disorder
- Antidepressants
References[edit]
External Links[edit]
-
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian